Summary Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of these patients responded. Nine patients received Cisplatinum and only one patient had a partial response. The trial suggests that chemotherapy has no place in the treatment of advanced salivary gland malignant tumours.
Malignant salivary gland neoplasms are characterised by a high risk of local recurrence (Budd & Groppe, 1983 ) and a tendency for local invasion. Nodal metastases occur late and 40% of all patients eventually develop distant metastases (Vermeer & Pinedo, 1979) . The latter are most frequent in the lungs, but may also occur in the bones, brain, liver, and other viscera. These characteristics are particularly common in adenoid cystic carcinoma. The four most common malignant salivary tumours cited in a large series (Spiro & Spiro, 1989) were mucoepidermoid (34%), adenoid cystic carcinoma (22%), adenocarcinoma (18%), and malignant mixed tumour (13%). Local recurrence is a particular problem with malignant salivary gland disease, and in one series the recurrence rate for tumours in the parotid, submandibular, and minor salivary glands was 39%, 60%, and 65% respectively (Spiro, 1986) . Consequently, adjunctive treatment, particularly with irradiation, is widely practiced (Shidnia et al., 1980) . Even so locoregional recurrence remains a persistent problem.
Malignant salivary gland tumours are relatively uncommon forming only 5% of all head and neck malignancies (Rentschler et al., 1977) and thus the experience in any one centre of treating these diseases is limited.
There is little information on the use of chemotherapy for advanced and recurrent malignant tumours as only small studies have been performed on a variety of agents. The most effective drugs are thought to be doxorubicin hydrochloride (dox), Hexamethylmelamine, Cisplatinum, and 5-Fluorouracil (Budd & Groppe, 1983; Vermeer & Pinedo, 1979; Rentschler et al., 1977; Johnson et al., 1964; Alberts et al.. 1981; Skibbia et al., 1981; Creagan et al., 1983; Richards & Chambers, 1973; Moore et al., 1968) . Dox and 5-Fluorouracil appear to be synergistic.
In the present study the efficacy of the less toxic dox analogue Epirubicin in combination with 5-Fluorouracil is compared with Cisplatinum in the palliation of advanced and recurrent malignant salivary tumours.
Patients and methods
A Phase II crossover study is reported (Herson, 1984 Criteria of response, duration of response, and toxicity were as laid down by Miller et al. (1981) , and patients were followed up fortnightly.
The number of patients needed for the trial was calculated using Gehan's rule (1961) . Fourteen patients were to be admitted initially, a number sufficient to detect a 20% response with a power of 95%. If no response had occurred the trial would have been terminated. In the event 16 patients were admitted to the trial (Tables I and II) .
Each tumour was carefully assessed and classified by site and stage (UICC, 1987 Creatinine clearance (ml min-') >60 50-60 <50 Cisplatinum (mg m 2) 100 50 0 and given over 6-8 h as an intravenous infusion. Post hydration was with 11 of normal saline over 2 h. The other group received Epirubicin (75 mg m-2) given over 6-8 h followed by 5-Fluorouracil (100 mg m2) given over 24 h as an intravenous infusion.
The total cumulative doses of Epirubicin did not exceed 700 mg m2 and of Cisplatinum, 600 mg m2.
Analysis of the data Survival curves were constructed using the method of Kaplan and Meier (1985) and were compared for the two groups using the log rank test (Peto et al., 1977) .
Categories of response for the two groups were compared by Fisher's test of exact probability.
Results
There was no response to treatment in the Epirubicin and 5-Fluorouracil group and only one partial response in those receiving Cisplatinum.
The median survival was 243 days for the Epirubicin/5-FU group and 450 days for the Cisplatinum group. The difference in survival was not significant (X2 = 0.3, d.f. = 1).
The results are displayed in Table III .
Discussion
Studies concerning malignant salivary gland tumours are rare and have concentrated on small numbers of patients exposed to a variety of chemetherapeutic agents including Methotrexate, 5-FU, dox, Hydroxyurea, C.C.N.U.
(1-(2-chlorethyl)-3-cyclohexyl-l-nitrosourea), Vincristine, Cisplatinum, Cyclophosphamide, Hexamethylmelamine, Bleomycin, and Chlorambucil (Budd & Groppe, 1983; Vermeer & Pinedo, 1979;  (X2 = 0.3, df= 1, N.S.) Rentschler et al., 1977; Johnson et al., 1964; Alberts et al., 1981; Skibba et al., 1981; Creagan et al., 1983; Richards & Chambers, 1973; Moore et al., 1968) . Some of these studies are case reports and some are trials. The two large chemotherapy series (Rentschler et al., 1977; Tannock & Sutherland, 1980) Creagan et al. (1983) in two separate studies using dox, Cyclophosphamide and Cisplatinum both achieved a complete response in two patients, the median duration of this response being 5 months. They also achieved a partial response in three and six patients respectively with a median duration of 6 months in both groups. Other studies (Budd & Groppe, 1983; Vermeer & Pinedo, 1979; Alberts et al., 1981; Tannock & Sutherland, 1980) reported partial responses with median durations of 5 weeks, 5 months, and 12 months.
Combination regimens, such as Cylcophosphamide/dox/ Cisplatinum (Alberts et al., 1981; Creagan et al., 1983) and Cyclophosphamide/dox/Vincristine (Skibba et al., 1981) show a very high response rate with a median duration ranging from 1 to 7 months. In the present study there was no response to Epirubicin/5-FU and the median survival was 243 days. There was one partial response in the Cisplatinum group and the median survival was 450 days. The difference was not significant.
Conclusions
(1) The optimistic view summarised in the Introduction is typical and biased -because only the good results tend to be reported. (2) Any difference in survival is difficult to analyse because of the well known unpredictable long term behaviour of salivary carcinoma and in particular adenoid cystic carcinoma. Therefore, for all these tumours, response is probably a better criterion than survival unlike squamous cell carcinoma where the converse is true. Furthermore, chemotherapeutic trials which fail to consider the effect of varying histology of malignant salivary gland tumours on response and survival should no longer be considered acceptable. (3) In this study both chemotherapeutic regimens produced equally disappointing results. (4) This trial suggests that chemotherapy is unhelpful in the treatment of end-stage salivary malignancy.
